Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Twist Bioscience Corporation (TWST) Misses Q2 EPS by 1c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus
May 6, 2021 5:15 PM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.78), $0.01 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $31.2 million versus the consensus estimate of $28.32 million.
FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS
Orders: Total orders received for the second quarter of fiscal 2021 were $41.7 million, compared to $24.6 million for the same period of fiscal 2020.Revenue: Total revenues were $31.2 million for the second quarter of fiscal 2021 compared to $19.3 million for the same period of fiscal 2020.Cost of Revenues: Cost of revenues for the second quarter of fiscal 2021 was $19.0 million... More